Lori J. Wirth
Harvard University · 580 works · 20,929 citations · h-index 69
Top works
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- Cabozantinib in Progressive Medullary Thyroid Cancer
- Structure of the Human MSH2 Locus and Analysis of Two Muir-Torre Kindreds for msh2 Mutations
- Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer
- Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- Selective RET kinase inhibition for patients with RET-altered cancers
- Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
- Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
- Dose to Larynx Predicts for Swallowing Complications After Intensity-Modulated Radiotherapy
- Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
- A Phase II Study of Gefitinib in Patients with Advanced Thyroid Cancer
- Thyroid Carcinoma
- Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
- NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- PD-1 Blockade in Anaplastic Thyroid Carcinoma